Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma

被引:56
作者
Morton, SJ [1 ]
Powell, RJ [1 ]
机构
[1] Univ Nottingham Hosp, Clin Immunol Unit, Nottingham NG7 2UH, England
关键词
scleroderma; cyclosporin; tacrolimus; skin tightness; side-effects;
D O I
10.1093/rheumatology/39.8.865
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Cyclosporin and tacrolimus are immunomodulatory drugs which act predominantly on T cells. Improvements in certain manifestations, particularly skin tightness, have been observed in a number of patients with scleroderma treated with these drugs. However, to date there have been no reports of their use in a routine clinical setting. Methods. Patients attending clinical immunology clinics who had progressive systemic sclerosis and related syndromes and who had received cyclosporin and/or tacrolimus were identified. Details of their treatment, including drug dosage, duration of and response to treatment, side-effects and reasons for withdrawal, were recorded. Results. Sixteen patients had been given cyclosporin and 13 of these had been treated for skin tightness. Half noticed significant softening of their skin whilst on treatment, and resolution was observed in all four of the patients treated for digital vasculitis. Side-effects were common and dose-limiting, and contributed to withdrawal in 12 out of 13 patients. Eight patients had been treated with tacrolimus; two of these had stopped the drug because of progression of their disease, one developed diarrhoea, prompting withdrawal, one stopped tacrolimus following improvement, and four remained on the drug. Side-effects had occurred in three patients. Conclusion. Improvements in skin occur in approximately half of all cases of scleroderma treated with either cyclosporin or tacrolimus, suggesting a beneficial effect. Side-effects, especially hypertension, are common with cyclosporin and often necessitate withdrawal. Adverse effects are also observed with tacrolimus, but in the small cohort so far treated only one patient had stopped the drug for this reason.
引用
收藏
页码:865 / 869
页数:5
相关论文
共 15 条
[1]   CYCLOSPORINE IN SUCCESSFUL CONTROL OF RAPIDLY PROGRESSIVE SCLERODERMA [J].
APPELBOOM, T ;
ITZKOWITCH, D .
AMERICAN JOURNAL OF MEDICINE, 1987, 82 (04) :866-867
[2]   CYCLOSPORINE IN SYSTEMIC-SCLEROSIS - RESULTS OF A 48-WEEK OPEN SAFETY STUDY IN 10 PATIENTS [J].
CLEMENTS, PJ ;
LACHENBRUCH, PA ;
STERZ, M ;
DANOVITCH, G ;
HAWKINS, R ;
IPPOLITI, A ;
PAULUS, HE .
ARTHRITIS AND RHEUMATISM, 1993, 36 (01) :75-83
[3]   SKIN COLLAGEN FROM SCLERODERMA PATIENTS BEFORE AND AFTER CYCLOSPORIN-A TREATMENT [J].
FRANCES, C ;
BRANCHET, MC ;
BLETRY, O ;
LEFEVRE, CH ;
BOISNIC, S ;
KERN, P ;
GODEAU, P .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1988, 13 (01) :1-3
[4]   SYNDROME RESEMBLING PROGRESSIVE SYSTEMIC-SCLEROSIS AFTER BONE-MARROW TRANSPLANTATION - MODEL FOR SCLERODERMA [J].
FURST, DE ;
CLEMENTS, PJ ;
GRAZE, P ;
GALE, R ;
ROBERTS, N .
ARTHRITIS AND RHEUMATISM, 1979, 22 (08) :904-910
[5]  
GISSLINGER H, 1991, CLIN EXP RHEUMATOL, V9, P383
[6]  
Knop J., 1985, CICLOSPORIN AUTOIMMU, P199
[7]   SIDE-EFFECTS OF SYSTEMIC CYCLOSPORINE IN PATIENTS NOT UNDERGOING TRANSPLANTATION [J].
PALESTINE, AG ;
NUSSENBLATT, RB ;
CHAN, CC .
AMERICAN JOURNAL OF MEDICINE, 1984, 77 (04) :652-656
[8]  
POWLES RL, 1980, LANCET, V1, P327
[9]   LYMPHOCYTES IN THE SKIN OF PATIENTS WITH PROGRESSIVE SYSTEMIC-SCLEROSIS - QUANTIFICATION, SUBTYPING, AND CLINICAL CORRELATIONS [J].
ROUMM, AD ;
WHITESIDE, TL ;
MEDSGER, TA ;
RODNAN, GP .
ARTHRITIS AND RHEUMATISM, 1984, 27 (06) :645-653
[10]  
RUSSELL ML, 1988, ARTHRITIS RHEUM, V31, P551